Positivity of high-sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non-HBV-related HCC.
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
04 Sep 2024
04 Sep 2024
Historique:
revised:
26
06
2024
received:
09
06
2024
accepted:
15
08
2024
medline:
4
9
2024
pubmed:
4
9
2024
entrez:
4
9
2024
Statut:
aheadofprint
Résumé
The prognostic impact of previous-HBV-infection (pHBV) in non-HBV-related hepatocellular carcinoma (non-HBV-related-HCC) and the prevalence, characteristics and significance of recently developed high-sensitivity HBs antigen positivity (hHBsAg+) in these patients remain unclear. We aimed to close these gaps. We retrospectively screened patients with newly diagnosed non-HBV-related-HCC (standard HBsAg-test negative) at Hokkaido University. Patients with complete clinical information and preserved serum for hHBsAg+ were included. We evaluated the prevalence, characteristics and prognostic impact of pHBV and hHBsAg+ in non-HBV-related-HCC. A total of 401 non-HBV-related-HCC patients were included (288 with pHBV/113 without pHBV). In non-HBV-related-HCC, pHBV did not affect overall survival (OS). Among non-HBV-related-HCC patients with pHBV, 11.8% (34/288) were hHBsAg+ and had more advanced stages of HCC, higher AFP levels, higher vascular invasion rates, and significantly shorter OS than others (OS: 19.3 vs. 61.4 months, p = 0.012). Comparison of OS among non-HBV-related-HCC patients without pHBV (group 1), those with pHBV and without hHBsAg+ (group 2), and those with pHBV and hHBsAg+ (group 3) revealed significantly shorter OS in group 3 (19.3, 56.6 and 66.4 months in groups 1, 2 and 3, respectively; p = 0.036). Multivariate Cox regression indicated that compared with group 1, only group 3 was significantly and independently associated with shorter OS (HR: 2.044, p = 0.011). Subgroup analysis revealed that this association was particularly evident in non-HBV-related-HCC patients with non-B-non-C aetiology and advanced HCC. In non-HBV-related-HCC patients, hHBsAg+, not pHBV, is significantly and independently associated with poor prognosis.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
The prognostic impact of previous-HBV-infection (pHBV) in non-HBV-related hepatocellular carcinoma (non-HBV-related-HCC) and the prevalence, characteristics and significance of recently developed high-sensitivity HBs antigen positivity (hHBsAg+) in these patients remain unclear. We aimed to close these gaps.
METHODS
METHODS
We retrospectively screened patients with newly diagnosed non-HBV-related-HCC (standard HBsAg-test negative) at Hokkaido University. Patients with complete clinical information and preserved serum for hHBsAg+ were included. We evaluated the prevalence, characteristics and prognostic impact of pHBV and hHBsAg+ in non-HBV-related-HCC.
RESULTS
RESULTS
A total of 401 non-HBV-related-HCC patients were included (288 with pHBV/113 without pHBV). In non-HBV-related-HCC, pHBV did not affect overall survival (OS). Among non-HBV-related-HCC patients with pHBV, 11.8% (34/288) were hHBsAg+ and had more advanced stages of HCC, higher AFP levels, higher vascular invasion rates, and significantly shorter OS than others (OS: 19.3 vs. 61.4 months, p = 0.012). Comparison of OS among non-HBV-related-HCC patients without pHBV (group 1), those with pHBV and without hHBsAg+ (group 2), and those with pHBV and hHBsAg+ (group 3) revealed significantly shorter OS in group 3 (19.3, 56.6 and 66.4 months in groups 1, 2 and 3, respectively; p = 0.036). Multivariate Cox regression indicated that compared with group 1, only group 3 was significantly and independently associated with shorter OS (HR: 2.044, p = 0.011). Subgroup analysis revealed that this association was particularly evident in non-HBV-related-HCC patients with non-B-non-C aetiology and advanced HCC.
CONCLUSIONS
CONCLUSIONS
In non-HBV-related-HCC patients, hHBsAg+, not pHBV, is significantly and independently associated with poor prognosis.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Agency for Medical Research and Development
ID : JP24fk0210126,JP24fk0310501,JP24fk0210121,JP24fk0210112,JP24fk0210142,JP24fk0210111,JP24fk0310524,JP24fk0210123,JP24fk0210157,JP24fk0310518,JP24fk0210103,JP24fk0210104,JP24fk0210113,andJP24fk0210143
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362(9399):1907–1917.
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2021;7(1):6.
Chidambaranathan‐Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1–61.
Pfister D, Nunez NG, Pinyol R, et al. NASH limits anti‐tumour surveillance in immunotherapy‐treated HCC. Nature. 2021;592(7854):450–456.
Rimini M, Kudo M, Tada T, Shigeo S, Kang W, Suda G, et al. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. ESMO Open. 2021;6(6):100330.
World Health Organization. Fact sheet: hepatitis B. 2021. Available from: https://www.who.int/news‐room/fact‐sheets/detail/hepatitis‐b
Ikeda K, Marusawa H, Osaki Y, Nakamura T, Kitajima N, Yamashita Y, et al. Antibody to hepatitis B core antigen and risk for hepatitis C‐related hepatocellular carcinoma: a prospective study. Ann Intern Med. 2007;146(9):649–656.
Lee HL, Bae SH, Lee J, Sung PS, Lee SW, Jang JW, et al. Effects of positive hepatitis B Core antibody and metabolic disorders in hepatocellular carcinoma in an endemic area of hepatitis B virus. Cancer Control. 2021;28:10732748211039758.
Coppola N, Onorato L, Sagnelli C, Sagnelli E, Angelillo IF. Association between anti‐HBc positivity and hepatocellular carcinoma in HBsAg‐negative subjects with chronic liver disease: a meta‐analysis. Medicine (Baltimore). 2016;95(30):e4311.
Lok AS, Everhart JE, Di Bisceglie AM, et al. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology. 2011;54(2):434–442.
Tatsuno K, Midorikawa Y, Takayama T, Yamamoto S, Nagae G, Moriyama M, et al. Impact of AAV2 and hepatitis B virus integration into genome on development of hepatocellular carcinoma in patients with prior hepatitis B virus infection. Clin Cancer Res. 2019;25(20):6217–6227.
Sung WK, Zheng H, Li S, Chen R, Liu X, Li Y, et al. Genome‐wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet. 2012;44(7):765–769.
Matsumoto A, Imaizumi M, Tanaka Y, Nishiguchi S, Yatsuhashi H, Ishida T, et al. Novel and highly sensitive immunoassay for total hepatitis B surface antigen, including that complexed with hepatitis B surface antibody. J Gastroenterol. 2017;52(3):376–384.
Meier MA, Calabrese D, Suslov A, Terracciano LM, Heim MH, Wieland S. Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load. J Hepatol. 2021;75(4):840–847.
Bruix J, Sherman M. Practice Guidelines Committee AAftSoLD management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208–1236.
Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Kimura M, et al. Entecavir treatment of hepatitis B virus‐infected patients with severe renal impairment and those on hemodialysis. Hepatol Res. 2019;49(11):1294–1304.
Suzuki K, Suda G, Yamamoto Y, et al. Tenofovir‐disoproxil‐fumarate modulates lipid metabolism via hepatic CD36/PPAR‐alpha activation in hepatitis B virus infection. J Gastroenterol. 2021;56(2):168–180.
Kawagishi N, Suda G, Sakamori R, Matsui T, Onozawa M, Yang Z, et al. Serum IL‐1beta predicts de novo hepatitis B virus reactivation during direct‐acting antiviral therapy for hepatitis C, not during anti‐cancer/immunosuppressive therapy. Sci Rep. 2022;12(1):16800.
Suda G, Baba M, Yamamoto Y, Sho T, Ogawa K, Kimura M, et al. Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation‐related hepatitis. J Med Virol. 2023;95:e28452.
Sasaki T, Suda G, Ohara M, Hosoda S, Kawagishi N, Kohya R, et al. Recent prevalence and characteristics of patients with hepatitis delta virus in Hokkaido, Japan. Hepatol Res. 2023;53(10):960–967.
Ozeki I, Nakajima T, Suii H, Tatsumi R, Yamaguchi M, Kimura M, et al. Analysis of hepatitis B surface antigen (HBsAg) using high‐sensitivity HBsAg assays in hepatitis B virus carriers in whom HBsAg seroclearance was confirmed by conventional assays. Hepatol Res. 2018;48(3):E263–E274.
Zucman‐Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology. 2015;149(5):1226–1239. e4.
Rimini M, Rimassa L, Ueshima K, Burgio V, Shigeo S, Tada T, et al. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non‐viral unresectable hepatocellular carcinoma: an international propensity score matching analysis. ESMO Open. 2022;7(6):100591.
Shinkai N, Matsuura K, Sugauchi F, Watanabe T, Murakami S, Iio E, et al. Application of a newly developed high‐sensitivity HBsAg chemiluminescent enzyme immunoassay for hepatitis B patients with HBsAg seroclearance. J Clin Microbiol. 2013;51(11):3484–3491.
Inoue T, Matsui T, Tanaka Y. Novel strategies for the early diagnosis of hepatitis B virus reactivation. Hepatol Res. 2021;51(10):1033–1043.
Oone K, Inoue T, Kusumoto S, Ohike T, Goto T, Sato S, et al. Clinical usefulness of a newly developed high‐sensitive hepatitis B surface antigen (HBsAg) assay for monitoring hepatitis B reactivation. Kanzo. 2019;60(60):237–247.
Okada K, Nakayama Y, Xu J, Cheng Y, Tanaka J. A nation‐wide medical record database study: value of hepatitis B surface antigen loss in chronic hepatitis B patients in Japan. Hepatol Res. 2024. https://doi.org/10.1111/hepr.14056. Online ahead of print.
Liu Y, Hu X, Hu X, Yu L, Ji H, Li W, et al. T follicular helper cells improve the response of patients with chronic hepatitis B to interferon by promoting HBsAb production. J Gastroenterol. 2022;57(1):30–45.